<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168156">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01895699</url>
  </required_header>
  <id_info>
    <org_study_id>2013Wze033</org_study_id>
    <nct_id>NCT01895699</nct_id>
  </id_info>
  <brief_title>The Effect of Contrast Agent on Endothelial Function in Healthy Men</brief_title>
  <official_title>The Effect of Contrast Agent on Endothelial Function in Healthy Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiang Guang-da</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan General Hospital of Guangzhou Military Command</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Contrast medium is essential for diagnosis of many diseases. However, recent studies showed
      that contrast agents can induce renal injury and is associated with poor long-term clinical
      outcome, especially in diabetes. To date, no data are available on the relationship between
      contrast medium and endothelial function. Endothelial dysfunction is known to precede
      atherosclerosis and is considered a risk marker for future development of cardiovascular
      disease. Therefore, we hypothesized that contrast agents may induce endothelial dysfunction
      in healthy men. In addition, we hypothesized that contrast induced endothelial dysfunction
      via free radicals. Thus, we also test alpha-lipoic acid whether or not protect endothelial
      dysfunction induced by contrast agents.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>The endothelial dysfunction and the protective role of alpha-lipoic acid</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The apoptosis of endothelial progenitor cell</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Contrast Agent</condition>
  <condition>Endothelial Function</condition>
  <condition>Cytokines</condition>
  <condition>Apoptosis of Endothelial Progenitor Cell</condition>
  <condition>Free Radical</condition>
  <condition>Alpha-lipoic Acid</condition>
  <arm_group>
    <arm_group_label>contrast group (Ioversol)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each individual will be given 80 ml Ioversol via intravenous injection within 5 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>alpha-lipoic acid group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Alpha-lipoic acid 600 mg in 0.9% sodium chloride 250 ml was administrated 1 hour before contrast agents via venous. and only 0.9% sodium chloride 250 ml was administrated for other 2 groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Contrast agent</intervention_name>
    <arm_group_label>contrast group (Ioversol)</arm_group_label>
    <arm_group_label>alpha-lipoic acid group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy men

          -  20 yr &lt; = age &lt; = 30 yr

          -  20 &lt; = body mass index &lt; = 25

        Exclusion Criteria:

          -  age &lt; 20 yr or &gt; 30 yr

          -  dysfunction for liver, renal, and heart.

          -  other diseases such as diabetes, hypertension, thyroid disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiang Guangda, MD</last_name>
    <phone>+8602768878410</phone>
    <email>Guangda64@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wuhan General Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiang Guangda, MD</last_name>
      <phone>+8602768878410</phone>
      <email>Guangda64@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan General Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Guangda, MD</last_name>
      <phone>+8602768879059</phone>
      <email>Guangda64@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>October 25, 2013</lastchanged_date>
  <firstreceived_date>July 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan General Hospital of Guangzhou Military Command</investigator_affiliation>
    <investigator_full_name>Xiang Guang-da</investigator_full_name>
    <investigator_title>Director of Endocrinol and Metab</investigator_title>
  </responsible_party>
  <keyword>Contrast agent</keyword>
  <keyword>endothelium</keyword>
  <keyword>Free radical</keyword>
  <keyword>Alpha lipoic acid</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
